BOSTON, April 30, 2019 — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include: Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögrens Giant[…]
December 18, 2018 – PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named OM1 as one of the most innovative Services of 2018. Founded in 2015, OM1 is a health outcomes and technology company leveraging big clinical data, standardized outcome measurement, and artificial intelligence[…]
November 15, 2018 —OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm. OM1’s Richard Gliklich and Michelle Leavy collaborated on the development of the measures and co-authored the publication. The work was funded by the Agency for Healthcare Research and Quality (AHRQ) through[…]
Published on PM360, April 2, 2018 The shift to value-based care and outcomes contracting type programs present the opportunity to align stakeholder interests around value and demonstrate a commitment to improving clinical and cost outcomes. From earlier detection to more precision management, the opportunities for pharma to partner around outcomes and value are growing. Win-wins[…]
Value-based care is gaining momentum and with that so too are outcomes-based contracts and risk sharing agreements. As payment models increasingly link outcomes to payment, there is a greater need for alignment of outcomes among different stakeholders. Join Dr. Richard Gliklich as he discusses the opportunities and challenges with: Defining measurable outcomes Developing and implementing[…]
